Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial.


Sorbonne Université, INSERM UMRS 1127 and CIC-1422, CNRS UMR, 7225, ICM, Assistance Publique Hôpitaux de Paris, CHU Pitié-Salpêtrière, Department of Neurology, Paris, France. Electronic address: [Email]


There is an unmet need to better control motor complications in Parkinson's disease (PD). Naftazone, which exhibits glutamate release inhibition properties, has shown antiparkinsonian and antidyskinetic activity in preclinical models of PD and in a clinical proof of concept study.


Clinical trial,Levodopa-induced dyskinesia,Naftazone,Parkinson's disease,